Genentech Eyes Top Oncology Spot By 2010; No Near-Term Avastin Competitor
Executive Summary
Genentech believes the first competitor to its oncologic Avastin in the angiogenesis market is "years away.
You may also be interested in...
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
Genentech R&D Spending Will Be 18% Of Revenue; Small Molecules In Plan
Genentech's long-term research & development investment will more closely resemble that of a pharmaceutical firm than a biotech company